Gene: CTCF (CCCTC-binding factor)
Location: Chromosome 16q22.1
Transcript: NM_006565.4
Protein: CTCF — 11 zinc-finger (ZF) DNA-binding protein critical for 3D genome organization, chromatin insulation, transcriptional regulation, and gene expression fidelity.
CTCF-related disorder (CRD) is caused by heterozygous loss-of-function (LoF) or dominant-negative variants affecting CTCF. To date, >160 distinct pathogenic or likely pathogenic variants have been reported. These include:
• Missense variants (~62% of nonsynonymous variants), enriched in:
o Zinc finger (ZF) domains — especially ZF3, ZF4, ZF5, ZF6 — critical for DNA binding and chromatin looping.
o RNA-binding domains (ZF1, ZF10, N-terminus).
o YDF domain (N-terminus), which regulates CTCF–cohesin interactions.
• Nonsense mutations and frameshift mutations leading to premature termination codons resulting in haploinsufficiency.
• Splice-site variants, in-frame deletions, and copy-number variants (CNVs):
o CNV deletions (leading to LoF)
o CNV duplications (CTCF is also sensitive to triplosensitivity; duplications can disrupt function).
• Noncoding variants affecting CTCF binding sites may contribute to neuropsychiatric phenotypes (e.g., schizophrenia), though their role in CRD remains to be fully elucidated.
Pathophysiological mechanism
• The predominant mechanism is haploinsufficiency — a single functional copy of CTCF is insufficient for normal chromatin architecture and gene regulation during neurodevelopment.
• Some missense variants within critical domains may exert dominant-negative effects or cause altered/aberrant DNA-binding patterns.
• Triplosensitivity (duplication intolerance) is also supported by CNV data.
• Functional studies show:
• Loss or alteration of CTCF binding at thousands of genomic loci.
• Disruption of chromatin loops and topologically associated domains (TADs).
• Aberrant gene expression profiles in patient-derived cells and animal models.
• Tissue-specific impacts on brain development, neuronal survival, and behavior.
Diagnostic Testing
• Genomic testing:
o Exome sequencing or targeted gene panels for neurodevelopmental disorders reliably detect SNVs and small indels in CTCF.
o Chromosomal microarray (CMA) can detect deletions and duplications encompassing CTCF.
• Variant interpretation:
o Pathogenicity assessment considers variant type, location (ZF domains are highly constrained), de novo status, in silico predictions, and phenotypic concordance.
o Many variants remain classified as variants of uncertain significance (VUS) pending additional functional or clinical data.
Summary
CTCF-related disorder arises from a broad spectrum of heterozygous CTCF variants—missense, truncating, splicing, and CNVs—that impair CTCF’s role as a master regulator of chromatin architecture and transcription during development. The molecular pathology reflects both haploinsufficiency and potential dominant-negative effects on genome organization. Comprehensive genomic testing with expert variant interpretation is essential for accurate diagnosis.
CTCF